XTEN Barcode Fragments for Truncation Variant Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for identifying and quantifying truncation variants in polypeptides are limited in sensitivity, efficiency, and effectiveness, which can affect the safety and efficacy of protein-based drugs by introducing unintended biological effects and immunogenicity.
Innovation Solution
The use of XTEN polypeptides with non-overlapping sequence motifs and barcode fragments that are releasable upon protease digestion, allowing for precise detection and quantification of truncation variants through proteolytic fragment analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing techniques are used to identify and quantifying truncation variants, then the detection can be performed, but the sensitivity, ease, and effectiveness are limited
Solution Approach 1:
The patent introduces an intermediary system consisting of unique sequence motifs and barcode fragments that mediate between the truncation variants and the detection method. These intermediaries enable highly sensitive and effective detection by providing specific, distinguishable markers for each polypeptide variant, resolving the limitation of existing detection techniques
Solution Approach 2:
The patent employs molecular 'color coding' through unique sequence motifs and barcode fragments that serve as distinct identifiers for different polypeptide variants. This approach enables clear differentiation and quantification of full-length versus truncated polypeptides, significantly improving measurement precision and detection effectiveness
2Ease of manufacture
If truncation variants are present in the polypeptide mixture, then the production process is simplified, but the safety and efficacy of the drug are compromised due to unintended active components and immunogenicity
Solution Approach 1:
The patent implements preliminary action by incorporating unique sequence motifs and barcode fragments into the polypeptide structure during production. This allows for the pre-establishment of detectable markers that enable subsequent identification and quantification of truncation variants, facilitating quality control without complicating the manufacturing process
Solution Approach 2:
The patent establishes a feedback mechanism through the use of barcode fragments that can be detected and quantified. This feedback system allows manufacturers to monitor the presence of truncation variants and adjust production parameters accordingly, ensuring drug safety and efficacy while maintaining production simplicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the detection and quantification of truncation variants, improving the safety and efficacy of protein-based drugs by reducing immunogenicity and maintaining therapeutic efficacy.
Implementation Method 1
a first barcode fragment releasable from the polypeptide upon digestion by a protease
Data Source
AI summary
Disclosed herein are polypeptides comprising an extended recombinant polypeptide (XTEN) comprised of a plurality of overlapping sequence motifs and one or more barcode fragments releasable upon protease digestion and detectable from ail other proteolytic-ally releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, wherein advantageous embodiments thereof comprise a releasable segment capable of proteolytic cleavage that cleaves the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making and methods of using said polypeptides are also disclosed.